Boudicca Dx

Dr. Gordon leads the consulting team at Boudicca Dx. She has biopharma, clinical laboratory & diagnostics industry experience built on top of technical acumen acquired from building molecular and cellular-based research assays to explore the phenomenon of cancer cell epithelial to mesenchymal transition (EMT) during her PhD training (Pharmacology) at Duke University.  This is when Dr. Gordon first became captivated with testing biological specimens to understand the underlying biology of disease. She had the opportunity to follow a pancreatic cancer tissue specimen taken from a patient in the operating room (distal pancreatectomy) to the pathology laboratory for testing to ensure the surgical margins were clean. Her passion became making sure that every precious specimen that leaves a patient’s body is maximally used to understand the biology of their disease to more effectively manage their disease & identify surgical or treatment options.

After completing two years of postdoctoral training in translational oncology, she built a biobank for Veterans Affairs (VA) clinical research & developed molecular diagnostic LDTs hands-on as a ASCP-certified molecular technologist in a Molecular Diagnostics CLIA-certified, CAP-accredited laboratory (VA Southern Arizona Healthcare System).

She has published on the development of an early breast cancer detection LDT in a CLIA, CAP laboratory (Provista Diagnostics). She developed CDx IVDs working at Roche Tissue Diagnostics (Ventana Medical Systems) and has held several executive roles at precision medicine companies (HTG Molecular, Loxo Oncology, & Kura Oncology). She was a Scientific Advisory Board (SAB) Member for two AI/ML biomarker discovery platforms (one was acquired & one out-licensed its predictive biomarker signature).

She is currently a SAB member for two companies (Cellens and Proteotype Diagnostics) developing tests incorporating novel clinical biomarkers.

If you need help with precision medicine development, reach out: kelly@boudiccadx.com

Publications:

• A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years

• Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer

• Role of transforming growth factor-beta superfamily signaling pathways in human disease

• The type III TGF-beta receptor suppresses breast cancer progression

• Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2

• Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression